Bicycle Therapeutics vs Standard BioTools
BCYC and LAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BCYC and LAB compare
Bicycle Therapeutics and Standard BioTools are about the same size, with market caps of $259M and $252M.
Bicycle Therapeutics grew revenue faster over the last twelve months (195% versus −4.8% for Standard BioTools).
Standard BioTools keeps more of each dollar of sales as profit, with a net margin of 100% compared with −170% at Bicycle Therapeutics.
Standard BioTools scores higher on the StockData Score (12 against 11 for Bicycle Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BCYC | LAB |
|---|---|---|
| Size and price | ||
| Market cap | $259M | $252M |
| Share price | $3.69 | $0.643 |
| Change, 1 year | −43.9% | −45.0% |
| Change, 5 years | −93.7% | −85.7% |
| Beta (5Y) | 1.39 | 1.53 |
| Employees | 288 | 389 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 3 | 4 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 2 | 3 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 2.9× |
| P/S | 3.1× | 3.0× (better) |
| P/B | 0.5× | 0.5× (better) |
| FCF yield | −68.4% | −32.7% (better) |
| Fair value | $16.38 | $4.90 |
| Margin of safety | 77.5% | 86.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 195% (better) | −4.8% |
| Revenue growth, 5Y average | 47.5% (better) | −9.2% |
| Profitability | ||
| Gross margin | – | 50.5% |
| Operating margin | −189% | −113% (better) |
| Net margin | −170% | 100% (better) |
| FCF margin | −212% | −97.6% (better) |
| Return on equity | −25.2% | 17.6% (better) |
| Return on invested capital | −4543% | −60.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −815.6× | – |
| Current ratio | 12.09 (better) | 9.10 |
| Altman Z-score | 0.26 (better) | −0.34 |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.00% | – |
| Years of dividend growth | 0 | – |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 53.4% | 75.4% |
| Held by insiders | 21.3% | 70.2% |
| Insider net buying, 12 months | −$523K | $550K (better) |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 1.9% |
Go deeper
- BCYC stock overview
- BCYC income statement
- BCYC valuation and score
- LAB stock overview
- LAB income statement
- LAB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.